Generic Xifyrm Availability
Last updated on Jul 9, 2025.
Xifyrm is a brand name of meloxicam, approved by the FDA in the following formulation(s):
XIFYRM (meloxicam - solution;intravenous)
-
Manufacturer: AZURITY
Approval date: June 5, 2025
Strength(s): 30MG/ML (30MG/ML) [RLD]
Is there a generic version of Xifyrm available?
No. There is currently no therapeutically equivalent version of Xifyrm available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Xifyrm. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Pharmaceutical liquid compositions of meloxicam
Patent 12,263,176
Issued: April 1, 2025
Inventor(s): Dubewar; Ashish Anilrao et al.
Assignee(s): SLAYBACK PHARMA LLC (Princeton, NJ)The present invention relates to stable injectable compositions comprising meloxicam or its pharmaceutically acceptable salts, solvates, or hydrates thereof, wherein the composition is provided in a sealed container, e.g., an ampoule, vial and pre-filled syringe. Further, the present invention relates to a stable injectable solution comprising meloxicam or its pharmaceutically acceptable salts, solvates, or hydrates thereof, suitable for subcutaneous, intravenous or intramuscular administration. The invention relates to methods for manufacturing stable injectable solutions of meloxicam. The present invention further relates to a method of treating pain by parenterally administering to a patient in need thereof a composition comprising a stable solution of meloxicam, wherein said solution provides rapid onset of action for pain relief compared to a reference composition.
Patent expiration dates:
- July 31, 2041✓
- July 31, 2041
More about Xifyrm (meloxicam)
- Check interactions
- Compare alternatives
- Latest FDA alerts (5)
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: Nonsteroidal anti-inflammatory drugs
- Breastfeeding
Patient resources
Other brands
Mobic, Anjeso, Vivlodex, Qmiiz ODT
Professional resources
Other brands
Mobic, Anjeso, Vivlodex, Qmiiz ODT
Related treatment guides
Related/similar drugs
Paracetamol
Paracetamol (Panadol, Calpol, Alvedon) is a widely used over-the-counter painkiller and fever ...
Tylenol
Tylenol is a pain reliever and a fever reducer used to treat many conditions such as headaches ...
Botox
Botox is used cosmetically to reduce facial lines and wrinkles and for medical purposes for ...
Naproxen
Naproxen is a nonsteroidal anti-inflammatory drug used to treat pain or inflammation caused by ...
Oxycodone
Oxycodone is an opioid analgesic used to treat moderate to severe pain; it has a high potential for ...
Diclofenac
Diclofenac is a nonsteroidal anti-inflammatory drug used to treat pain and inflammation associated ...
Cyclobenzaprine
Cyclobenzaprine is a muscle relaxant and works by blocking pain sensations. Includes ...
Hydroxyzine
Hydroxyzine is an antihistamine used to treat itching, hives, and anxiety. It also acts as a ...
Tramadol
Tramadol is an opioid medication that may be used to treat moderate to moderately severe chronic ...
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.